Pharmaceuticals company Kwality Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights Revenue from operations (Net) for Q4FY26 stood at Rs 15,711.36 lakh, representing a growth of 27.28% QoQ compared to Rs 12,343.97 lakh in Q3FY26 and a YoY growth of 35.82% compared to Rs 11,567.64 lakh in Q4FY25. Total Revenue for Q4FY26 was Rs 15,817.17 lakh, an increase of 27.59% QoQ from Rs 12,396.74 lakh and 35.84% YoY from Rs 11,644.18 lakh. Profit After Tax (PAT) for Q4FY26 reached Rs 2,531.05 lakh, showing a significant growth of 58.19% QoQ from Rs 1,600.00 lakh in Q3FY26 and a growth of 74.80% YoY compared to Rs 1,447.99 lakh in Q4FY25. For the full year FY26, consolidated Revenue from operations (Net) reached Rs 50,308.34 lakh, marking a 35.90% increase from Rs 37,019.70 lakh in FY25. The Consolidated Profit After Tax for FY26 was Rs 6,734.60 lakh, representing a YoY growth of 69.20% compared to Rs 3,980.27 lakh in FY25. PAT margins for FY26 expanded to 13.4%, up from 10.8% in FY25. Basic Earnings Per Share (EPS) for FY26 stood at Rs 64.90, compared to Rs 38.36 in FY25. Standalone Financial Highlights Revenue from operations (Net) for Q4FY26 stood at Rs 15,682.24 lakh, recording a QoQ increase of 27.04% from Rs 12,344.45 lakh and a YoY increase of 35.57% from Rs 11,567.64 lakh. Total Revenue for Q4FY26 reached Rs 15,788.04 lakh, growing by 27.35% QoQ and 35.59% YoY. Profit After Tax (PAT) for Q4FY26 was Rs 2,529.11 lakh, reflecting a QoQ growth of 58.00% and a YoY growth of 74.44%. For the full year FY26, standalone Revenue from operations (Net) was Rs 50,305.89 lakh, up 35.89% from Rs 37,019.70 lakh in FY25. Standalone Profit After Tax for FY26 reached Rs 6,734.66 lakh, compared to Rs 3,988.97 lakh in FY25, registering a growth of 68.83% YoY. Basic Earnings Per Share (EPS) for FY26 was Rs 64.90, compared to Rs 38.44 in FY25. Business Highlights The company delivered a landmark financial performance in FY26, achieving its highest-ever quarterly and annual revenues and fulfilling the strategic revenue commitment outlined in FY23. EBITDA margins improved to 24% during FY26, an expansion of approximately 200 basis points from 22% in FY25, driven by an improved product mix and higher contributions from regulated markets. KPL clearing multiple international regulatory and customer audits, and its credit rating was upgraded by ICRA to BBB+ from B+. A large-scale Bioequivalence (BE) program was initiated, covering more than 40 Oral Solid Dosage (OSD) molecules to support global filings. Success was achieved in pre-clinical outcomes for Erythropoietin ("Kwalipoietin"), the company’s first biologic, which is on track for a planned FY27 launch. The company improved its overall cash conversion cycle from 208 days to 170 days and has recovered nearly 30% of delayed receivables from Middle Eastern partners. Management has targeted a doubling of revenues over the next three years, with an aspirational milestone of Rs 1,00,000 lakh by FY29. The company remains on track to achieve its FY27 guidance of Rs 65,000 lakh in revenues and Rs 10,000 lakh in PAT. Segment Performance: The company is primarily engaged in the business of Pharmaceuticals, which is its single reportable segment. Exceptional Items: The company recognised an exceptional expense of Rs 82.94 lakh in FY26 related to the incremental impact of new Labour Codes on past service cost for gratuity liability. Result PDF